Matthew Rausch - The University of Arizona

基本信息

浏览量：18

职业迁徙

个人简介

Matthew does research in Oncology, Clinical Immunology and Hematology. Their most recent publication is 'Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application'.

研究兴趣

论文共 54 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Endogenous IL-27 During Toxoplasmosis Limits Early Monocyte Responses and Their Inflammatory Activation by Pathological T Cells

Daniel L. Aldridge,Devapregasan Moodley,Jeongho Park,Anthony T. Phan,Matthew Rausch,Kerry F. White, Yue Ren, Karin Golin,Enrico Radaelli,Ross Kedl,Pamela M. Holland,Jonathan Hill,Christopher A. Hunter

MBIO（2024）

引用0浏览0WOS引用

SRF617 is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties

Michael C Warren,Stephan Matissek,Matthew Rausch,Marisella Panduro, R J Hall,Austin Dulak, David Brennan, Sonia Das Yekkirala,Secil Koseoglu,Ricard Masia, Yu Yang, Navamallika Reddy, Robert Prenovitz,Jamie Strand, Tauqueer Zaidi,Erik Devereaux,Célia Jacoberger Foissac,John Stagg,Benjamin H Lee,Pamela Holland,Vito J Palombella,Andrew C Lake

ImmunoHorizonsno. 5 (2023): 366-379

引用1浏览0WOS引用

489 NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity

McKenna Lamb,Yao Wei,Xiaoxin Ren, Rachel O'Connor,Austin Dulak,Matthew Rausch,Jamie Strand,Bijan Etemad-Gilbertson, Riale Gilligan, Scott Chappel,Tomonari Shigemura,David McDermott,Gordon Freeman,XingXing Zang

Regular and Young Investigator Award Abstracts (2022): A510-A510

引用0浏览0引用

Abstract 1137: Determination of a Recommended Phase 2 Dose (RP2D) for SRF388, a First-in-class IL-27-blocking Antibody, in Patients with Advanced Solid Tumors

Jonathan A. Hill,Kerry F. White,Matthew Rausch,Jou-Ku Chung,Amita Patnaik,Aung Naing,Daniel Morgensztern,Charlene M. Mantia,Nizar M. Tannir,Lon S. Smith,Beth Bowers,Alex Alika,Lauren C. Harshman,Benjamin H. Lee

Cancer research（2022）

引用0浏览0引用

Abstract 1802: CD39 Inhibition Shapes the Transcriptional Landscape of Myeloid Cells and Induces Proinflammatory States in the CT26 Syngeneic Tumor Model

Devapregasan Moodley,Mayra Carneiro, Sonia D. Gas,Austin Dulak,Ricard Masia,Secil Koseoglu,Matthew Rausch,Marisella Panduro,Michael C. Warren,John Stagg,Benjamin Lee,Pamela M. Holland,Vito J. Palombella,Andrew C. Lake

Cancer research（2021）

引用1浏览0引用

247 the Fully Human Antibody SRF617 is a Potent Inhibitor of Ecto-Enzyme CD39 in Vivo

Stephan Matissek,Marisella Panduro Sicheva,Secil Koseoglu,Ricard Masia,Michael Warren,Matthew Rausch,Benjamin Lee,Sandra Pommey,Isabelle Cousineau,John Stagg,Vito Palombella,Andrew Lake

Regular and Young Investigator Award Abstracts（2021）

引用0浏览0引用

Abstract 1607: IL-27 Signaling Serves As an Immunological Checkpoint for NK Cells to Promote Hepatocellular Carcinoma in Multiple Murine Models

Turan Aghayev,Aleksandra M. Mazitova,Matthew Rausch,Kerry F. White,Jing Hua,Devapregasan Moodley,Secil Koseoglu,Ricard Masia,Benjamin H. Lee,Pamela M. Holland,Vito J. Palombella,Jonathan A. Hill,Kerry S. Campbell,Sergei I. Grivennikov,Ekaterina K. Koltsova

Immunology（2021）

引用0浏览0引用

Srf231, A Fully Human Cd47 Antibody, Potentiates The Effects Of Opsonizing Antibodies And Cytotoxic Chemotherapies In Preclinical Cancer Models

Kshama A. Doshi,Matthew Rausch,Caroline M. Armet,Li Zhang,Alison M. Paterson,Benjamin H. Lee,Vito J. Palombella,Pamela Holland,Marisa O. Peluso

CANCER RESEARCH（2020）

引用0浏览0引用

727 Increased Serum Levels of EBI3 Are Associated with Poor Outcome in Hepatocellular Carcinoma Patients and SRF388, a First-in-class IL-27 Blocking Antibody, Inhibits the Growth of Murine Liver Tumors

Matthew Rausch,Devapregasan Moodley,Marisa Peluso,Secil Koseoglu,Jing Hua,Gege Tan,Ricard Masia,Benjamin Lee,Isabelle Cousineau,Simon Turcotte,John Stagg,Vito Palombella,Pamela Holland,Jonathan Hill

Regular and Young Investigator Award Abstracts（2020）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn